Linda Stein Gold: Quality of Life and Clinical Efficacy Findings from PSOARING 1 and PSOARING 2
Touch Medical Media coverage of data presented at EADV 2022:
PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) were two phase 3 trials investigating tapinarof cream, a novel, steroid-free, AhR modulating agent for the treatment of plaque psoriasis. It was a pleasure to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) around the aims, design, endpoints and quality of life and clinical efficacy findings from the two pivotal phase 3 trials.
The abstract ‘Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials.’ (Abstract number: 1175) was presented at EADV 2022, 7-10 September, 2022.
Questions
- What were the aims and design of the PSOARING 1 and PSOARING 2 studies? (0:18)
- How well were the endpoints of the studies achieved? (1:16)
- What were the findings that you presented at EADV? (2:17)
Disclosures: Linda Stein Gold discloses consulting for Dermavant, Arcutis, Leo and Ortho Derm; receiving grant/ research support from Dermavant, Arcutis, Leo and Ortho Derm; serving on advisory boards for Dermavant, Arcutis, Leo and Ortho Derm; receiving honoraria from Dermavant, Arcutis, Leo and Ortho Derm and participating in speaker’s bureaus for Dermavant, Arcutis, Leo and Ortho Derm.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
